JP2019116423A - Composition for intestinal regulation - Google Patents

Abstract

To provide a novel composition for intestinal regulation.SOLUTION: A composition for intestinal regulation contains Lactobacillus paracasei NITE BP-01633 as an active ingredient.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a composition for intestinal regulation. In particular, the present invention relates to a composition for intestinal regulation, which comprises Lactobacillus paracasei NITE BP-01633 as an active ingredient.

  Enterobacteria constitute the gut microbiota and influence physiological conditions. Intestinal function is aggravated by irregular living and lack of exercise such as lack of exercise, hormonal imbalance, mental stress, etc., leading to defecation disorder such as constipation and diarrhea. In addition, abdominal pain, nausea and the like may occur due to defecation disorder. In addition, intestinal function may be deteriorated due to a serious disease or symptom, a symptom or a disorder, etc., resulting in defecation disorder. Therefore, search for an active ingredient having an effect of improving intestinal function, that is, an intestinal regulation effect is being performed.

Until now, a stool frequency and stool flow rate improving agent containing killed Lactobacillus brevis and lactoferrin as active ingredients is known (Patent Document 1).
In addition, a defecation promoter containing bifidobacteria, lactic acid bacteria and natto bacteria is known (Patent Document 2).
Furthermore, an oral composition comprising a placenta, a lactic acid bacterium and a hydrogen source as active ingredients is known, and the lactic acid bacterium is preferably Lactobacillus paracasei MCC 1849 (Patent Document 1) 3).
However, it is not known that Lactobacillus paracasei NITE BP-01633 exerts an intestinal regulation effect in subjects who ingested it (including the case where it was "administered").

In addition, a growth promoter for lactic acid bacteria is known which contains a dead cell of a Lactobacillus bacterium as an active ingredient (Patent Document 4).
In addition, a bifidobacteria growth promoting substance is known which comprises a culture supernatant of a propionic acid bacterium or a treated product thereof as an active ingredient (Patent Document 5).
Furthermore, viable bacteria of Lactobacillus gaserii NY0509 and / or viable bacteria of Lactobacillus casei NY1301 may be Bifidobacterium longum JCM 1217T, Bifidobacterium adressensis JCM 1275T, Bifidobacterium breve JCM 1192T. It is known that the mixed culture with B. and B. has an effect of promoting the growth of Bifidobacterium (Non-patent Document 1).
In addition, nano-type lactic acid bacteria are known which have an effect of enhancing the ability to produce interferon α from antigen-presenting cells by physically destroying dead bacteria of lactic acid bacteria to reduce the cell diameter (Patent Document 6). .
Furthermore, a lipid metabolism improving agent is known which is a lipid metabolism improving agent containing cell destruction products of lactic acid bacteria as an active ingredient, wherein the average major axis of cells in the cell destruction products is 0 to 70% before destruction. (Patent Document 7).
However, Lactobacillus paracasei NITE BP-01633 is not known to promote the growth of Bifidobacterium bacteria and to promote the growth of Lactobacillus bacteria.

JP, 2014-11668, A JP 2001-169749 A JP, 2017-012104, A Patent No. 5592048 Patent No. 3121046 Patent No. 4054697 Patent No. 5801802

Journal of Japan Society for Food Science and Technology, 48, 9 (2001)

  An object of the present invention is to provide a novel composition for intestinal regulation.

  The present inventors have found that Lactobacillus paracasei NITE BP-01633 exerts an intestinal regulation effect in a subject who has taken the cells (including the case where it is administered), and completes the present invention. It came to

That is, the present invention is a composition for intestinal regulation, which comprises Lactobacillus paracasei NITE BP-01633 as an active ingredient.
In a preferred embodiment, the composition for intestinal regulation is that Lactobacillus paracasei NITE BP-01633 is heat-killed.
In a preferred embodiment, the composition for intestinal adjustment is that the heat-killed Lactobacillus paracasei NITE BP-01633 is crushed.
The composition for intestinal regulation is preferably used for the prevention or treatment of defecation disorder.
In the composition for regulating intestine, it is a preferred embodiment that the defecation disorder is constipation or diarrhea.
The composition for intestinal adjustment is characterized in that the constipation or diarrhea is irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or The preferred embodiment is constipation or diarrhea resulting from a systemic disease.
In a preferred embodiment, the composition for intestinal regulation is that the constipation is delayed transit-type constipation, functional constipation, organic constipation or drug-induced constipation.
In the composition for regulating intestine, it is preferable that the diarrhea is caused by food poisoning, infectious enteritis, ulcerative colitis or food allergy.
In a preferred embodiment, the composition for intestinal regulation further comprises Bifidobacterium bacteria and / or Lactobacillus bacteria (except Lactobacillus paracasei NITE BP-01633).
In a preferred embodiment, the composition for intestinal regulation is that the Bifidobacterium bacteria are derived from the intestinal tract of a mammal.
In a preferred embodiment, the composition for intestinal regulation is that the mammal is a human.
The composition for intestinal regulation is such that the Bifidobacterium genus bacteria is Bifidobacterium longum subspecies longum, Bifidobacterium infantis, Bifidobacterium breve, or Bifidobacterium. -The preferred embodiment is bifidum.
The Lactobacillus genus bacteria (however, Lactobacillus paracasei NITE BP-01633 is excluded) are the said composition for intestinal regulation, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus delviium. It is a preferred embodiment that it is Ricky subspecies vulgaricus or Lactobacillus lactis.
It is preferable that the composition for intestinal regulation is a food and drink composition.
The composition for intestinal regulation is preferably a pharmaceutical composition.

  According to the present invention, a novel composition for intestinal regulation can be provided.

Average number of stools vs. pre-observation period for the group receiving the jelly containing the heat-killed powder of Lactobacillus paracasei NITE BP-01633 and the group receiving the placebo jelly not containing the heat-sterilized powder (control group) A diagram representing values. The number of Bifidobacterium bifidum ATCC 29521 after culture for a predetermined time in the case of containing a heat-killed body of Lactobacillus paracasei NITE BP-01633 or its sonicated product and in the case of neither containing Diagram to represent. The number of Bifidobacterium adressensis ATCC 15703 after culture for a predetermined period of time with and without the heat-killed body of Lactobacillus paracasei NITE BP-01633 or its sonicated product Diagram representing Indicates the number of Lactobacillus plantarum ATCC 14917 after cultivation for a predetermined period of time with and without the heat-killed body of Lactobacillus paracasei NITE BP-01633 or its sonicated product and without any of them. Figure.

Hereinafter, the present invention will be described in detail.
The composition for intestinal regulation of the present invention comprises Lactobacillus paracasei NITE BP-01633. Hereinafter, the same bacterial body may be described as "the bacterial cell of the present invention", "the present bacterial cell", or "NITE BP-01633".

  The composition for intestinal adjustment of the present invention is a concept including a mixture, and it does not matter whether the components of the composition for intestinal adjustment are uniform or nonuniform.

NITE BP-01633 which is an active ingredient of the composition for intestinal regulation of the present invention has an intestinal regulation effect. The intestinal regulation action in the present invention means an action to improve intestinal function. Specifically, for example, as in the case of constipation to be described later, it means a defecation promoting action to increase the number of defecation times and / or defecation amount of the subject, when the number of defecation frequency and / or defecation amount is small When the subject ingests the present organism (including the case of "administered" herein), the number of stools is greater than when not ingesting (including the case of "not administered" herein). It means that the amount of defecation is large. Specifically, it is preferable that the number of defecations is two or more times, preferably three or more times, more preferably three or more times per week, than when the subject ingests the present microbial cells. It is preferable that the number is more than that.
On the other hand, as in the case of diarrhea described later, when the number of stools and / or the amount of stools of the subject are large, it means a defecation suppressing action to reduce the number of stools and / or the amount of stools of the subjects. The number of bowel movements and / or stool volume is more than when not taking (when “in administration” is included here), when not taking (here, when “in administration” is included). Means less. Specifically, the number of stools is the number of times per day, preferably one or more times less, and more preferably two or more times less than when the subject ingests the cells. More preferably, it is less than three times.

  On June 6, 2013, this bacterial cell was collected from the National Institute of Technology and Evaluation, National Institute of Technology and Evaluation, Biotechnological Center, Patent Microorganisms Depositary Center (NPMD) (〒 292-0818, Kisarazu City, Chiba Prefecture 2-5-8, Room 122) The deposit number is assigned to NITE P-01633, and is transferred to the international deposit under the Budapest Treaty on December 19, 2013. The deposit number is assigned to NITE BP-01633.

The present bacterial cells are not limited to the above-mentioned deposited bacterial cells, and may be bacteria substantially equivalent to the above-mentioned deposited bacterial cells. The bacteria substantially equivalent to the deposited bacteria are Lactobacillus paracasei, and
When the subject ingests the bacterium, it can exert an intestinal regulation effect, and the base sequence of the 16S rRNA gene is preferably 98% or more relative to the base sequence of the 16S rRNA gene of the deposited bacterial cell. And more preferably 99% or more, more preferably 100% homology, and preferably, bacteria having the same bacteriological properties as those of the above-mentioned deposited cells. In addition, the present strain also includes a mutant strain and a genetically modified strain which have the strain as a parent strain.

  The present cells can be easily obtained, for example, by culturing the same cells. The method for culturing is not particularly limited as long as the present cells can grow, and a method usually used for culturing Lactobacillus bacteria (Lactic acid bacteria) can be appropriately modified and used as necessary. For example, the culture temperature may be 25 to 50 ° C, preferably 35 to 42 ° C. Culturing may be performed under either aerobic or anaerobic conditions, but it is preferable to carry out under anaerobic conditions. For example, culturing can be performed while aerating an anaerobic gas such as carbon dioxide gas. Moreover, you may culture | cultivate on micro aerobic conditions, such as liquid stationary culture.

  The medium in which the present bacterial cells are cultured is not particularly limited, and a medium usually used for culture of Lactobacillus bacteria (Lactic acid bacteria) can be appropriately modified and used as necessary. That is, as the carbon source, for example, saccharides such as galactose, glucose, fructose, mannose, cellobiose, maltose, lactose, sucrose, trehalose, starch, starch hydrolysate, waste molasses and the like can be used according to assimilability. As a nitrogen source, for example, ammonium salts such as ammonia, ammonium sulfate, ammonium chloride, ammonium nitrate and nitrates can be used. As the inorganic salts, for example, sodium chloride, potassium chloride, potassium phosphate, magnesium sulfate, calcium chloride, calcium nitrate, manganese chloride, ferrous sulfate and the like can be used. In addition, organic components such as peptone, soybean powder, defatted soybean meal, meat extract, and yeast extract may be used. In addition, as a prepared medium, for example, an MRS medium can be suitably used.

  The present culture may be used as it is after the culture, or may be used after dilution or concentration, or may be used after collection from the culture. In addition, various additional operations such as heating and lyophilization can be performed after the culture, as long as the effects of the present invention are not impaired. Furthermore, the present bacterial cells may be live bacteria or dead bacteria, but are preferably dead bacteria, and examples of dead bacteria include dead bacteria killed by heating, lyophilization and the like. Other dead cell preparation methods include spray drying (spray drying), retort sterilization, freeze drying, UHT sterilization, pressurized sterilization, high pressure steam sterilization, dry heat sterilization, circulating steam sterilization Electromagnetic wave sterilization method, electron beam sterilization method, high frequency sterilization method, radiation sterilization method, ultraviolet ray sterilization method, ethylene oxide gas sterilization method, hydrogen peroxide gas plasma sterilization method, chemical sterilization method (alcohol sterilization method, formalin fixation method, electrolysis Water treatment method). Also, the cells may be crushed. The crushed material may be one obtained by crushing viable bacteria or one obtained by crushing dead bacteria, or may be one obtained by heating or lyophilization after crushing.

In addition, crushing can be selected, for example, crushing by physical crushing, enzyme dissolution treatment, chemical treatment, autolysis treatment or the like using methods and equipment known in the art.
Physical disruption may be carried out by either treatment in the form of cell suspension or treatment in the form of cell powder. As an example of physical crushing, crushing by stirring using ultrasonic homogenizer, homogenizer, ball mill, bead mill, dyno mill, planetary mill etc., crushing by pressure using jet mill, French press, cell crusher etc, filter filtration processing Crushing by damaging the cells can be selected.
As the enzyme dissolution treatment, for example, an enzyme such as lysozyme can be used to destroy the cell structure of the lactic acid bacterial cell.
As the drug treatment, surfactants such as soybean phospholipid and glycerin fatty acid ester can be used to destroy the cell structure of lactic acid bacterial cells.
As the autolysis treatment, lactic acid bacterial cells can be dissolved with some enzymes of lactic acid bacteria themselves.
In the present invention, physical crushing is preferable because it is not necessary to add other chemicals or compounds.

As described later, since the present bacterial cell promotes the growth of Bifidobacterium bacteria and / or Lactobacillus bacteria (but excluding the present bacterial cell), the intestinal regulation action in the present invention is It is considered that the growth of Bifidobacterium bacteria and / or Lactobacillus bacteria (but excluding the present bacteria) is promoted in a subject who received the cells.
Therefore, it is preferable that the composition for intestinal regulation of the present invention further comprises Bifidobacterium bacteria and / or Lactobacillus bacteria (but excluding the present bacteria). In addition, Bifidobacterium bacteria may also be 1 type or multiple types also in Lactobacillus genus bacteria (However, this microbial cell is remove | excluded.). In addition, as described later, the present cell is also used as a composition for promoting the growth of Bifidobacterium bacteria and / or Lactobacillus bacteria.

  It is preferable that Bifidobacterium bacteria are derived from mammalian intestinal tract. For example, Bifidobacterium longum subspecies longum (Bifidobacterium longum subsp. Longum), Bifidobacterium infantis (Bifidobacterium infantis), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium breve Bifidobacterium (Bifidobacterium bifidum), Bifidobacterium adescentis (Bifidobacterium adolescentis), Bifidobacterium catenulatum (Bifidobacterium catenulatum), Bifidobacterium animalis (Bifidobacterium animalis), Bifidobacterium shoudronium (Bifidobacterium (Bifidobacterium) pseudolongum), Bifidobacterium boum and the like.

Mammals include humans, cows, sheep, goats, pigs, dogs, cats, horses and the like.
Among the above-mentioned Bifidobacterium bacteria, Bifidobacterium bacteria derived from the human intestinal tract are Bifidobacterium longum subspecies longum (Bifidobacterium longum subsp. Longum), Bifidobacterium infan Tis (Bifidobacterium infantis), Bifidobacterium breve (Bifidobacterium breve), Bifidobacterium bifidum (Bifidobacterium bifidum), Bifidobacterium adolescentis, Bifidobacterium catenulatum (Bifidobacterium catenatum) It is.

  Among them, specific examples of Bifidobacterium bifidum include Bifidobacterium bifidum ATCC 29521 (Bifidobacterium bifidum ATCC 29521) and their mutant strains. In addition, specific examples of Bifidobacterium adolescentis include Bifidobacterium adolescent ATCC 15703 (Bifidobacterium adolescentis ATCC 15703), their mutant strains, and the like. All of the above-mentioned cells can be obtained from the American Type Culture Collection (Address: 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

Examples of Lactobacillus bacteria (but excluding the present bacterium) include, for example, Lactobacillus plantarum, Lactobacillus casei (Lactobacillus).
casei), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus lactis (Lactococcus lactis) and the like.

  Among them, specific examples of Lactobacillus plantarum include Lactobacillus plantarum ATCC 14917 and their mutant strains. The cells can be obtained from the American Type Culture Collection (Address: 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

The composition for intestinal regulation of the present invention has an intestinal regulation action, and can be used for the prophylaxis or treatment of diseases, symptoms, symptoms or disorders which can be prevented or treated by intestinal regulation. In other words, it can be used for the prevention or treatment of diseases, symptoms, symptoms or disorders that can be prevented or treated by improving intestinal function. "Treatment" also includes improvement. Also, the subject may have one or more diseases, symptoms, symptoms or disorders, and the like.
Among these, the disorder includes, for example, defecation disorder.
Defecation disorders include, for example, constipation, diarrhea and the like. In the present specification, diarrhea includes fecal incontinence.
Constipation is a disorder that refers to a state in which defecation becomes difficult, includes firm stools, struggling to defecate, cases where there are no defecation for several days, etc., and the number of defecations and / or the amount of defecation are small.
Diarrhea is a disorder in which a very loose gel (chew) or liquid stool is excreted as compared to normal stool, and is referred to as soft stool, muddy stool, watery stool, etc. And / or the amount of defecation is large.
Fecal incontinence is a disorder that unconsciously or unintentionally causes bowel movements, and the number of bowel movements and / or the number of bowel movements are large. Examples of fecal incontinence include stress fecal incontinence, urge fecal incontinence, overflow fecal incontinence, functional fecal incontinence and the like.

Specific examples of constipation and diarrhea include irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease etc. Constipation or diarrhea may be caused. Examples of intestinal obstruction include intestinal paralytic ileus and the like. Further, specific examples of diarrhea further include diarrhea caused by food poisoning, infectious enteritis, ulcerative colitis, food allergy and the like.
In addition, constipation includes, for example, delayed transit-type constipation, functional constipation, organic constipation or drug-induced constipation.

The composition for intestinal regulation of the present invention can be used as a food and drink composition, a pharmaceutical composition or a feed composition. For example, it is possible to provide a food and drink composition for intestinal adjustment, a pharmaceutical composition for intestinal adjustment, and a feed composition for intestinal adjustment.
The composition for intestinal regulation of the present invention includes a composition for oral (including oral) and a composition for oral (including oral) which contains a placenta, Lactobacillus paracasei NITE BP-01633 and a hydrogen source. It is preferable to remove

The food-drinks composition for intestinal adjustment of the present invention is not particularly limited as long as it contains the present microorganism. The food and drink composition may be in the form of liquid, paste, gel-like solid, powder, etc., and may be food or drink. Besides tablet cakes, liquid food etc., for example, bread, macaroni, spaghetti, noodles , Cake mix, Flour products from fried flour, bread crumbs, etc. Instant noodles, cup noodles, retorts, cooked foods, cooked cans, microwave oven foods, instant soups and stews, instant miso soup, soups, soup cans, freezes, dried foods, etc Instant foods such as ready-to-eat instant foods etc .; Canned agricultural products, canned fruits, jams and marmalades, pickles, boiled beans, dried agricultural products such as agricultural products, cereals (processed cereal products), etc .; canned fish, ham ham, sausage, fishery Processed fish products, processed fish products such as fishery delicacies, dried bonito, etc .; Canned products, pastes, processed meat products such as meat ham, sausage, etc .; Processed milk, milk drinks Milk and dairy products such as yogurts, lactic acid bacteria beverages, cheese, ice creams, prepared milk powders, creams and other dairy products; Fats and oils such as butter, margarines and vegetable oils; soy sauce, miso, sauces, tomato processing Basic seasonings such as seasonings, mirins and vinegars; Cooked mixes, ingredients of curry, sauces, dressings, noodles, spices and other complex seasonings such as complex seasonings and foods; Frozen ingredients Frozen foods such as semi-cooked frozen foods and cooked frozen foods; caramel, candy, gummi, chewing gum, chocolate, cookies, biscuits, cakes, pies, snacks, crackers, Japanese sweets, rice sweets, bean sweets, dessert sweets, jellies , And other confectioneries; carbonated beverages, natural juices, juices, juices with juices, fruit juices, fruit juices with berries Vegetable beverages, soy milk, soy milk beverages, coffee beverages, tea beverages, powdered beverages, concentrated beverages, sports beverages, nutritional beverages, alcoholic beverages, other favorite beverages such as favorite beverages, baby food, sprinkles, tea dumplings, etc. Other marketed foods, etc .; formulated milk powder for child care; enteral nutritional food; special purpose food, health food (food for specified health use, food for nutrition function, food for functional indication);
The food and drink composition may be a supplement, for example, a tablet-like supplement. In the case of a supplement, the cells can be taken without being influenced by the amount of food and calories consumed per day.

The food and drink composition for intestinal tract adjustment of the present invention can be produced by adding the present microbial cells to the raw materials of the usual food and drink, and is the same as the ordinary food and drink except that the present microbial cells are added. Can be manufactured. The addition of the present microbial cells may be performed at any stage of the process of producing the food and drink composition. Moreover, the food-drinks composition may be manufactured through the fermentation process by the this microbial cell added. As such food-drinks composition, a lactic-acid-bacteria drink, fermented milk, etc. are mentioned.
As a raw material of a food-drinks composition, the raw material used for a normal food-drinks can be used. The manufactured food and drink composition can be taken orally.

  The food and drink composition for intestinal regulation of the present invention also includes raw materials for producing the food and beverage composition, and food additives such as food additives which are added to the food and beverage composition after the production process or production of the food and beverage composition. Be For example, the present cells can be used as a starter for producing fermented milk. In addition, the cells can also be added later to the produced fermented milk.

  In addition, the food and drink composition for intestinal tract adjustment of the present invention uses a component having a probiotic effect or a component that aids a probiotic effect, which is known or is to be found in the future, as long as the effect of the present invention is not impaired can do. For example, the food / beverage composition for intestinal regulation of the present invention includes various proteins such as whey protein, casein protein, soy protein, or pea protein (pea protein) or mixtures thereof, decomposition products; leucine, valine, isoleucine or glutamine, etc. Amino acids; vitamins such as vitamin B6 or vitamin C; creatine; citric acid; fish oil; or components such as isomaltoligosaccharides, galactooligosaccharides, xylooligosaccharides, soybean oligosaccharides, fructooligosaccharides, oligosaccharides such as lactulose, It can be formulated by blending with the present cells.

Although the content of the present microbial cells in the food and drink composition for intestinal regulation of the present invention is appropriately set according to the aspect of the food and drink composition, it is usually 1 × 10 ⁴ to 1 × 10 ^{13 in the} food and drink composition. It is preferably in the range of cfu / g or 1 × 10 ⁴ to 1 × 10 ¹³ cfu / ml, and 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / ml It is more preferable to be in the range of "Cfu" represents colony forming unit. When the cells are dead cells, cfu / g or cfu / ml can be replaced with single cells / g or single cells / ml. When the present cells are disrupted, cfu / g or cfu / ml or single cell / g or single cell / ml is the cfu / g or cfu / ml or single cell / g or single cell / ml of viable cells or It can be replaced with a crush of dead bacteria.

The food-drinks composition for intestinal tract adjustment of the present invention may be taken alone, and other food-drinks composition or food-drinks or pharmaceutical composition or medicine, for example, other food-drinks composition or food-drinks for eating or drinking Goods or pharmaceutical composition or medicine, food or drink composition or food or drink or pharmaceutical composition or medicine for the prevention or treatment of diseases, symptoms, symptoms or disorders that can be prevented or treated by the intestinal tract It is also good.

  The food-drinks composition for intestinal adjustment of this invention can be sold as a food-drinks composition or food-drinks in which the use with the for intestinal adjustment was displayed. Moreover, the food / beverage composition or food / beverage composition for which the use for preventing or treating a disease, a symptom, a symptom or a disorder, etc. which can be prevented or treated by the intestine adjustment is displayed. It can be sold as goods. Moreover, the food-drinks composition or food-drinks for intestines adjustment of this invention can be displayed, such as "for intestines adjustment." Further, it is needless to say that other than this, it can be used as long as it is a term indicating an effect which is generated secondarily by intestinal adjustment.

  Moreover, the food-drinks composition for intestines adjustment of this invention can be provided and sold as a food-drinks composition or food-drinks in which the use (including health use), such as probiotics, was displayed. In addition, those who wish to live living with bifidobacteria, those who want to improve the intestinal environment, those who want to improve their stomach condition, and those who are good at eating as food and drink compositions or food and drink consumption subjects It can be displayed and offered / sold as “one who wants to form an environment”.

The above "display" means all actions for making a consumer know the above-mentioned application, and if it is a display that can recall or infer the above-mentioned application, the purpose of display, the contents of display, display The terms “display” of the present invention are all applicable regardless of the target object and medium. However, it is preferable to display by the expression which a consumer can recognize the said application directly.
Specifically, an act of describing the use in the food or beverage composition for intestinal surgery of the present invention or a package of a product or merchandise pertaining to the food or beverage for intestine adjustment, or a package of the product or merchandise described in the application is transferred , Display for delivery, transfer or delivery, act of importing, advertisement for goods, price list or transaction document with the above application described and exhibited or distributed, or the information containing the above And the act etc. provided by electromagnetic (Internet etc.) method etc. can be illustrated, and in particular, display on advertising materials, other documents etc. at sales sites such as packaging, containers, catalogs, brochures, POP etc. is preferable.

  Moreover, it is preferable that it is a display permitted by administration etc. (For example, the display which receives an approval based on the various systems which administration determines, and is performed in the aspect based on such an approval) as a display. For example, it is possible to exemplify the display as health food, such as health food, health food, functional food, enteral nutrition food, special purpose food, nutritional function food, non-commercial item for medical use, etc. And other indications approved by the Consumer Agency, for example, food for specified health food, nutritive function food, functional indication food, indication approved in a similar system. Examples of the latter include labeling as food for specific health, labeling as food for conditional health, labeling indicating that the structure or function of the body is affected, disease risk reduction labeling, functionality based on scientific evidence Can be illustrated. More specifically, as a food for specified health specified in the Cabinet Office Ordinance (August 31, 2011 Cabinet Office Ordinance No. 57) concerning permission etc. of special use labeling prescribed in the Health Promotion Law. In particular, the display of health applications and the like.

  The pharmaceutical composition for intestinal regulation of the present invention is not particularly limited as long as it contains the present cells. The pharmaceutical composition for intestinal regulation of the present invention may be used as it is, or it may be formulated and formulated using a physiologically acceptable liquid or solid pharmaceutical carrier.

  The dosage form of the pharmaceutical composition for intestinal regulation of the present invention is not particularly limited, and specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, syrups, suppositories, Injections, ointments, patches, eye drops, nasal drops and the like can be exemplified. In addition, upon formulation, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent, a diluent, a surfactant, a solvent for injection, etc., which are usually used as a pharmaceutical carrier, are added. Agents can be used.

  In addition, as the pharmaceutical carrier, various organic or inorganic carriers can be used depending on the dosage form. Carriers in the case of solid preparations include, for example, excipients, binders, disintegrants, lubricants, stabilizers, flavoring agents and the like.

  Excipients include, for example, sugar derivatives such as lactose, sucrose, glucose, mannitol, sorbite, starch derivatives such as corn starch, potato starch, α-starch, dextrin, carboxymethyl starch, etc. crystalline cellulose, hydroxypropyl cellulose, Cellulose derivatives such as hydroxypropyl methylcellulose, carboxymethylcellulose and carboxymethylcellulose calcium; gum arabic; dextran; pullulan; light anhydrous silicic acid, synthetic aluminum silicate, silicate derivatives such as magnesium metasilicate aluminosilicate; phosphate derivatives such as calcium phosphate; Examples thereof include carbonate derivatives such as calcium; sulfate derivatives such as calcium sulfate and the like.

  Examples of the binder include gelatin, polyvinyl pyrrolidone, macrogol and the like in addition to the above-mentioned excipients.

  Examples of the disintegrant include, in addition to the above-mentioned excipients, chemically modified starch or cellulose derivatives such as croscarmellose sodium, sodium carboxymethyl starch and crosslinked polyvinyl pyrrolidone.

  Lubricants include, for example, talc; stearic acid; metal salts of stearic acid such as calcium stearate and magnesium stearate; colloidal silica; waxes such as pea gum and geew wax; boric acid; glycols; carboxylic acids such as fumaric acid and adipic acid Sodium carboxylic acid sodium salts such as sodium benzoate; sulfuric acid salts such as sodium sulfate; leucine; lauryl sulfates such as sodium lauryl sulfate and magnesium lauryl sulfate; silicic acids such as anhydrous silicic acid and silicic acid hydrate; starch derivatives etc. Be

  Examples of the stabilizer include p-hydroxybenzoic acid esters such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol and phenylethyl alcohol; benzalkonium chloride; acetic anhydride; sorbic acid and the like.

Examples of flavoring agents include sweetening agents, acidulants, flavors and the like.
As a carrier to be used in the case of liquid preparation for oral administration, solvents such as water, flavoring agents and the like can be mentioned.

The content of the present microbial cells in the pharmaceutical composition for intestinal tract adjustment of the present invention is appropriately set according to the dosage form, dosage, age of the subject, sex, subject, disease or symptom, type of symptom or disorder, degree thereof, and other conditions. However, in general, it is preferably in the range of 1 × 10 ⁴ to 1 × 10 ¹³ cfu / g or 1 × 10 ⁴ to 1 × 10 ¹³ cfu / ml, and 1 × 10 ⁷ to 1 × 10 ¹¹ cfu More preferably, it is in the range of 1 / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / ml. When the cells are dead cells, cfu / g or cfu / ml can be replaced with single cells / g or single cells / ml. When the present cells are disrupted, cfu / g or cfu / ml or single cell / g or single cell / ml is the cfu / g or cfu / ml or single cell / g or single cell / ml of viable cells or It can be replaced with a crush of dead bacteria.

The administration time of the pharmaceutical composition for intestinal tract adjustment of the present invention is not particularly limited, and it is possible to appropriately select the administration time according to the method for preventing or treating the target disease, symptom, symptom or disorder. Also, they may be administered prophylactically and may be used for maintenance therapy. In addition, it is preferable that the administration form is determined according to the form of preparation, age, sex, other conditions of the patient, degree of symptoms of the patient, and the like. In addition, the pharmaceutical composition for intestinal tract adjustment of the present invention can be administered once or several times a day in any case, and may be administered once in several days or several weeks. Subjects include humans, cows, sheep, goats, pigs, dogs, cats, horses and the like.

  The pharmaceutical composition for intestinal regulation of the present invention may be administered alone, or other pharmaceutical composition or pharmaceutical or food or beverage composition or food or beverage, for example, other intestinal pharmaceutical composition or medicament or food or beverage Pharmaceutical composition or food or drink, pharmaceutical composition or medicine for diseases or symptoms, symptoms or disorders that can be prevented or treated by the intestinal tract or the like (eg, anticancer agent etc.) or food or drink composition or food or beverage, constipation drug, You may use together with a gastrointestinal medicine, a laxative, an diarrhea stop, an analgesic, etc.

  Examples of the feed composition for intestinal adjustment of the present invention include pet food, livestock feed, fish feed and the like. The feed composition for intestinal regulation of the present invention can be used as a general feed or its raw material, for example, cereals, fish, fish, fish meal, bone meal, fats and oils, skimmed milk powder, whey, mineral feed, or yeasts etc. It can be produced by mixing the present cells. Also, for example, as in silage, a feed composition may be produced through a fermentation process with the added cells of the present invention. The produced feed composition can be orally administered to general mammals, livestock, fish farming, pets and the like.

The content of the present microbial cells in the feed composition for intestinal adjustment of the present invention is appropriately set depending on the form of the feed composition and the subject of administration, but 1 × 10 ⁶ to 1 × 10 ¹² cfu / g or 1 × 10 ⁶ It is preferably in the range of 1 × 10 ¹² cfu / ml, more preferably in the range of 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / g or 1 × 10 ⁷ to 1 × 10 ¹¹ cfu / ml. preferable. When the cells are dead cells, cfu / g or cfu / ml can be replaced with single cells / g or single cells / ml. When the present cells are disrupted, cfu / g or cfu / ml or single cell / g or single cell / ml is the cfu / g or cfu / ml or single cell / g or single cell / ml of viable cells or It can be replaced with a crush of dead bacteria.

Another aspect of the present invention relates to Lactobacillus paracasei NITE in the preparation of a composition for intestinal regulation.
It is the use of BP-01633.
Another aspect of the present invention is Lactobacillus paracasei NITE BP-01633 used for intestinal regulation.
In addition, another aspect of the present invention improves intestinal function of a subject, which comprises administering Lactobacillus paracasei NITE BP-01633 to the application subject, or administering the composition for intestinal regulation of the present invention to the application subject How to
In addition, another aspect of the present invention is the prevention or treatment by intestinal tract comprising administering Lactobacillus paracasei NITE BP-01633 to the application subject or administering the composition for intestinal regulation of the present invention to the application subject Methods of preventing or treating diseases or symptoms, symptoms or disorders that may be

Another aspect of the present invention is a composition for promoting the growth of Bifidobacterium bacteria, which comprises Lactobacillus paracasei NITE BP-01633 as an active ingredient.
Lactobacillus paracasei NITE BP-01633 used in the present invention has an action to promote the growth of Bifidobacterium bacteria. “Promoting growth” includes the case of ingesting (herein, “not administered”) when ingesting (including the case of “administered” herein) the present bacterial body. 2.) It means that the number of Bifidobacterium bacteria is greater than sometimes. Moreover, when Bifidobacterium bacteria are cultured in a culture medium, it means that the number of bacteria is greater in the culture medium containing the present bacteria than in the culture medium not containing the present bacteria.

The detailed description of the present embodiment incorporates the detailed description of the composition for intestinal regulation of the present invention, except for the following.
The average particle size of the crushed material of the present invention is, for example, a laser diffraction / scattering particle size distribution measuring device (LA-9).
It is preferably 80% or less, more preferably 70% or less, and further preferably 60% or less of the average particle diameter of the present cell before crushing, as measured by 50 V 2 (manufactured by HORIBA). On the other hand, it is preferably 1% or more, more preferably 2% or more, and still more preferably 4% or more.
In addition, examples of Bifidobacterium bacteria include those described in the detailed description of the composition for intestinal regulation of the present invention. Specifically, Bifidobacterium breve FERM BP-11175 (Bifidobacterium breve FERM BP-11175), Bifidobacterium breve BCCM LMG 23729 (Bifidobacterium breve BCCM LMG 23729), Bifidobacterium longum subspecies Longum ATCC BAA-999 (Bifidobacterium longum subsp. Longum ATCC BAA-999), Bifidobacterium bifidum ATCC 29521 (Bifidobacterium bifidum ATCC 29521), Bifidobacterium adescentis ATCC 15703 (Bifidobacterium adolescentis ATCC 15703), and Those mutant strains and the like can be mentioned.
As of August 25, 2009, the cells assigned with the accession number of FERM BP-11175 are: Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depositary, National Institute of Technology and Evaluation, Patent Organism Depositary, Postal Code: 292-0818, Address: 2-5-8, Azusa, Kisarazu, Chiba Pref., International Deposit under the Budapest Treaty.
Bacterial cells having a BCCM accession number can be obtained from Belgian Coordinated Collections of Microorganisms (Address: B-1000, Brussels-Cyans Avenue (Waitens Cup Avenue) 8), which is a preservation organization of Belgium.
Bacterial cells assigned the ATCC accession number can be obtained from the American Type Culture Collection (address: 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

  Another aspect of the present invention is a composition for promoting the growth of a Lactobacillus bacterium (but excluding the present cells), which comprises the present cells as an active ingredient. The present cells have an action to promote the growth of Lactobacillus bacteria (but excluding the present cells). "Promoting growth" is defined in the same manner as "promoting growth" in a composition for promoting the growth of Bifidobacterium bacteria.

The detailed description of the present embodiment incorporates the detailed description of the composition for promoting the growth of Bifidobacterium bacteria, which comprises the above-mentioned present cells as an active ingredient, except for the following.
Examples of Lactobacillus bacteria (but excluding the present bacteria) include, for example, those described in the detailed description of the composition for intestinal regulation of the present invention. Specifically, Lactobacillus plantarum ATCC 14917 (Lactobacillus plantarum ATCC 14917), a mutant strain of the strain, and the like can be mentioned. This cell can be obtained from the American Type Culture Collection (address: 12301 Parklawn Drive, Rockville, Maryland 20852, United States of America).

The composition for promoting the growth of Bifidobacterium bacteria and the composition for promoting the growth of Lactobacillus bacteria (but excluding the present bacteria) may be either a food or drink composition, a pharmaceutical composition, or a feed. It can be used as a composition. For example, a food composition for promoting growth, a pharmaceutical composition for promoting growth, and a feed composition for promoting growth can be provided.
All growth promoting compositions also include growth promoting agents (including oral use) and growth promoting compositions (oral use) containing a placenta, Lactobacillus paracasei NITE BP-01633 and a hydrogen source. It is preferable to remove
The detailed description of the food composition for promoting growth, the pharmaceutical composition for promoting growth, and the feed composition for growth is the food and drink composition for intestinal tract adjustment of the present invention, the pharmaceutical composition for intestinal tract adjustment, intestinal tract preparation according to the present invention, respectively. The detailed description of the feed composition is incorporated herein by reference.

Another aspect of the present invention is the use of Lactobacillus paracasei NITE BP-01633 in the manufacture of a composition for promoting the growth of Bifidobacterium bacteria.
Another aspect of the present invention is Lactobacillus paracasei NITE BP-01633 used for promoting the growth of Bifidobacterium bacteria.
In addition, another aspect of the present invention comprises administering Lactobacillus paracasei NITE BP-01633 to an application subject, or administering a composition for promoting the growth of Bifidobacterium bacteria to an application subject It is a method of promoting the growth of Fidobacterium bacteria.
In addition, another aspect of the present invention comprises administering Lactobacillus paracasei NITE BP-01633 to an application subject, or administering a composition for promoting the growth of Bifidobacterium bacteria to an application subject It is a method for preventing or treating a disease, a symptom, a symptom or a disorder that can be prevented or treated by promoting the growth of the genus Fidobacteria.
In any of the embodiments, as a specific description thereof, the composition for intestinal regulation of the present invention, and the composition for promoting the growth of Bifidobacterium bacteria comprising Lactobacillus paracasei NITE BP-01633 as an active ingredient Incorporate

Another aspect of the present invention is the use of Lactobacillus paracasei NITE BP-01633 in the manufacture of a composition for promoting the growth of a Lactobacillus bacterium (but excluding the present bacterium).
Another aspect of the present invention is Lactobacillus paracasei NITE BP-01633 used for promoting the growth of Lactobacillus bacteria (but excluding the present bacterium).
Furthermore, another aspect of the present invention is the step of administering Lactobacillus paracasei NITE BP-01633 to the application subject, or the composition for promoting the growth of Lactobacillus bacteria (but excluding the present bacterial body). A method of promoting the growth of Lactobacillus bacteria (but excluding the present bacteria), which comprises the steps of
Furthermore, another aspect of the present invention is the step of administering Lactobacillus paracasei NITE BP-01633 to the application subject, or the composition for promoting the growth of Lactobacillus bacteria (but excluding the present bacterial body). And a method for preventing or treating a disease, symptom, symptom or disorder that can be prevented or treated by promoting the growth of Lactobacillus bacteria (but excluding the present bacterial body).
In any of the embodiments, the composition for intestinal regulation of the present invention, and a Lactobacillus bacterium comprising Lactobacillus paracasei NITE BP-01633 as an active ingredient, as the specific description thereof (but excluding the present bacteria). The description of the growth promoting composition of

  Hereinafter, the present invention will be more specifically described using examples, but the present invention is not limited to these examples.

Preparation Example 1 Preparation of Heat-killed Lactobacillus paracasei NITE BP-01633 A bacterial cell of Lactobacillus paracasei NITE BP-01633 is cultured in MRS (de Man Rogosa Sharpe) medium (manufactured by BD) for 16 hours, After washing twice with PBS and once with distilled water, it was suspended in distilled water and heat-treated at 100 ° C. for 15 minutes. After the heat treatment, the cells were washed twice with distilled water, suspended in distilled water, and lyophilized to obtain a heat-killed product.

[Test Example 1] Effect of Lactobacillus paracasei NITE BP-01633 on human defecation promotion
A placebo-controlled, double-blind, randomized, controlled trial was conducted on elderly people aged 65 years and older.
42 elderly people were divided into the following intake group and control group. The intake group consisted of 21 people who ingested one jelly a day, containing a bactericidal powder (10 billion) obtained by heating the cells of Lactobacillus paracasei NITE BP-01633, and the control group Consists of 21 people who take 1 placebo placebo jelly a day. Among them, the number of bowel movements in the intake group of 20 people and the control group of 15 weeks was recorded for the pre-observation period of 2 weeks before intake, 6 weeks during the intake period, and 2 weeks after intake.
Table 1 and FIG. 1 show the average value of the change in stool frequency (times / week) with respect to the pre-observation period in the first week to the sixth week of the intake period and in the post-observation period. No change was observed in the number of stools in the control group, but a marked increase in the number of stools was observed from week 1 to week 6 during the intake period in the intake group, and the control group was also prominent in the post-observation period Exceeded. From the above results, it was confirmed that oral intake of Lactobacillus paracasei NITE BP-01633 increased the number of stools.

[Test Example 2] Growth promoting effect of Bifidobacterium bacteria by Lactobacillus paracasei NITE BP-01633 (1) A solution containing a heat-killed body of Lactobacillus paracasei NITE BP-01633 and its ultrasonicated material Preparation of Solution The heat-killed product of Lactobacillus paracasei NITE BP-01633 prepared in Production Example 1 was dissolved in sterile water to a concentration of 0.5 g / ml to prepare 50 mL of a solution containing the heat-killed product.
Also, the bacteria powder which has been similarly heat-sterilized is crushed using an ultrasonic homogenizer (BRABSON SONIFIER (registered trademark) 450, manufactured by BRABSON Ultrasonic) (output 60%, dial 3) to be 0.5 g / ml. The solution was dissolved in sterile water to prepare a solution containing 50 mL of a crushed product of the heat-killed body. The cell diameter after crushing was measured by a laser diffraction / scattering particle size distribution measuring apparatus (LA-950V2, manufactured by HORIBA).

(2) Pre-culture of Bifidobacterium bacteria As bifidobacteria, Bifidobacterium bifidum ATCC 29521 and Bifidobacterium adressensis ATCC 15703 were pre-cultured. Specifically, 1% glucose was added to the LB fermentation test culture medium shown in Table 3 (Mitsuoka Tomoko "Study of Bifidobacterium," p. 309, Bifidobacterium Center, published in 1994) to prepare 1% glucose, After sterilization, the above-mentioned cells belonging to the genus Bifidobacterium were inoculated 3% and precultured anaerobically at 37 ° C. for 16 hours.

(3) Measurement of the number of Bifidobacterium bacteria after culture from mixed culture with Bifidobacterium bacteria 1% glucose-added LB fermentation test medium (by Mitsuoka Tomoko "Study of Bifidobacterium" p. 309, ( Bifidobacteria center (published in 1994) was prepared, and after autoclave sterilization, it was aseptically dispensed into a 96-well plate. A heat-killed body of Lactobacillus paracasei NITE BP-01633 or its sonicated substance is added to the aliquoted culture medium to 0.01%, 2.5 × 10 ⁹ cells / well (1 × 10 ¹⁰ cells / mL), and further added. The viable cells of the above-mentioned cells belonging to the genus Bifidobacterium were inoculated at 10 ⁶ to 10 ⁸ CFU / mL and cultured anaerobically at 37 ° C. for 8, 16, 24 hours. In addition, what used the culture medium of equal volume instead of the said viable cell was set as control.
The cells of the wells cultured for 8, 16, 24 hours were collected and subjected to DNA extraction. DNA extraction was performed by the bead-phenol method (Matsuki Takahiro, “Method for extracting DNA from fecal samples”, Enteric Bacteriology Journal, 20: 259-262, 2006). The above belonging to the genus Bifidobacterium by quantitative PCR method using a genus specific primer (Ezaki Takayuki, "Identification of enteric flora: DNA probe and primer, Enteric bacteriology journal, 20: 245-258, 2006) The number of proliferating bacteria was analyzed.

(4) Results The results of Bifidobacterium bifidum ATCC 29521 are shown in Table 4 and FIG. 2, and the results of Bifidobacterium adressensis ATCC 15703 are shown in Table 5 and FIG. In both Bifidobacterium bifidum ATCC 29521 and Bifidobacterium adensisis ATCC 15703, growth is promoted both when Lactobacillus paracasei NITE BP-01633 is a heat-killed product and when it is an ultrasonicated product. Was confirmed.

[Test Example 3] Growth promoting effect of Lactobacillus bacteria (but excluding this cell) by Lactobacillus paracasei NITE BP-01633 In Test Example 2, Lactobacillus bacteria instead of Bifidobacterium bacteria. The same as in Test Example 2 except that Lactobacillus plantarum ATCC 14917 was used as a bacterium.
The results are shown in Table 6 and FIG. It was confirmed that the growth of Lactobacillus plantarum ATCC 14917 is promoted both when Lactobacillus paracasei NITE BP-01633 is a heat-killed product and when it is an ultrasonicated material.

Production Example 2
Lactobacillus paracasei NITE BP-01633 is added to 3 mL of MRS liquid medium, and after anaerobic culture at 37 ° C. for 16 hours, cells are washed three times by centrifugation and resuspension in distilled water, and then 10 with distilled water. mg
It is suspended so as to be (dry weight of cells) / ml and heat-killed at 100 ° C. for 15 minutes to make a solution containing a heat-killed body. The solution containing the heat-killed product is concentrated and lyophilized to obtain lyophilized powder (fungi powder) of each bacterium. A powder is obtained by uniformly mixing each bacterial powder with whey protein concentrate (WPC). 20 g of the composition is dissolved in 200 g of water to obtain a composition for intestinal regulation.
By administration of the present composition, an intestinal regulation effect can be expected. Furthermore, the prevention of constipation or diarrhea caused by irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease Or it can be used for treatment. Moreover, it can be used for the prevention or treatment of diarrhea resulting from food poisoning, infectious enteritis, ulcerative colitis or food allergy.

Production Example 3
Lactobacillus paracasei NITE BP-01633 is added to 3 mL of MRS liquid medium, and after anaerobic culture at 37 ° C. for 16 hours, cells are washed three times by centrifugation and resuspension in distilled water, and then 10 with distilled water. mg
It is suspended so as to be (dry weight of cells) / ml and heat-killed at 100 ° C. for 15 minutes to make a solution containing a heat-killed body. The solution containing the heat-killed product is concentrated and lyophilized to obtain lyophilized powder (fungi powder) of each bacterium. Next, crystalline cellulose is introduced into a stirring granulator and mixed. Thereafter, purified water is added to granulate, and the granulate is dried to obtain a granulate containing an extract of each bacterium and containing an excipient. By administration of the present composition, an intestinal regulation effect can be expected. Furthermore, prevention or constipation or diarrhea caused by irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease It can be used for treatment. Moreover, it can be used for the prevention or treatment of diarrhea resulting from food poisoning, infectious enteritis, ulcerative colitis or food allergy.

Production Example 4
Lactobacillus paracasei NITE BP-01633 is added to 3 mL of MRS liquid medium, and after anaerobic culture at 37 ° C. for 16 hours, cells are washed three times by centrifugation and resuspension in distilled water, and then 10 with distilled water. mg
It is suspended so as to be (dry weight of cells) / ml and heat-killed at 100 ° C. for 15 minutes to make a solution containing a heat-killed body. The solution containing the heat-killed product is concentrated and lyophilized to obtain a freeze-dried powder (fungal powder) of the bacteria. The bacterial powder and the oligosaccharide are uniformly mixed to obtain a composition. The composition is provided as a prebiotics material. The intake of Lactobacillus paracasei NITE BP-01633 is adjusted to 1 × 10 ⁸ to 1 × 10 ¹⁰ CFU / kg body weight / day, and served daily for 1 week. When Lactobacillus paracasei NITE BP-01633 is dead, CFU / kg body weight / day can be replaced with individual cells / kg body weight / day. In addition, you may mix with food-drinks, such as fermented milk. As oligosaccharides, isomaltooligosaccharides, lactulose, raffinose, fructooligosaccharides, galactooligosaccharides, soybean oligosaccharides can be used.
By administration of the present composition, an intestinal regulation effect can be expected. Furthermore, prevention or constipation or diarrhea caused by irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease It can be used for treatment. Moreover, it can be used for the prevention or treatment of diarrhea resulting from food poisoning, infectious enteritis, ulcerative colitis or food allergy.

Production Example 5
Lactobacillus paracasei NITE BP-01633, added to 3 mL MRS liquid medium and anaerobically cultured at 37 ° C. for 16 hours, the cells are washed three times by centrifugation and resuspension in distilled water, and then 10 with distilled water mg
It is suspended so as to be (dry weight of cells) / ml and heat-killed at 100 ° C. for 15 minutes to make a solution containing a heat-killed body. The solution containing the heat-killed product is concentrated and lyophilized to obtain a freeze-dried powder (fungal powder) of the bacteria. The composition is homogeneously mixed with oligosaccharides by mixing the bacteria powder with Bifidobacterium longum subspecies longum BB 536 (ATCC BAA-999) and / or Bifidobacterium breve LMG23729. obtain. The composition is provided as a prebiotics material. The intake of Lactobacillus paracasei NITE BP-01633 is adjusted to 1 × 10 ⁸ to 1 × 10 ¹⁰ CFU / kg body weight / day, and served daily for 1 week. When Lactobacillus paracasei NITE BP-01633 is dead, CFU / kg body weight / day can be replaced with individual cells / kg body weight / day. In addition, you may mix with food-drinks, such as fermented milk. As oligosaccharides, isomaltooligosaccharides, lactulose, raffinose, fructooligosaccharides, galactooligosaccharides, soybean oligosaccharides can be used.
By administration of the present composition, an intestinal regulation effect can be expected. Furthermore, prevention or constipation or diarrhea caused by irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease It can be used for treatment. Moreover, it can be used for the prevention or treatment of diarrhea resulting from food poisoning, infectious enteritis, ulcerative colitis or food allergy.

Production Example 6
The manufacturing method of fermented milk which added Lactobacillus paracasei NITE BP-01633 is shown below.
First, a milk raw material, water according to necessity, other components, etc. are mixed, preferably subjected to homogenization treatment, and heat-sterilized. The homogenization treatment and the heat sterilization treatment can be performed by a conventional method. A lactic acid bacteria starter is added (inoculated) to the heat-killed pasteurized milking solution, and fermentation is carried out by maintaining the temperature at a predetermined fermentation temperature to obtain a fermented product. The curd forms a curd.
As the lactic acid bacteria starter, for example, lactic acid bacteria commonly used for producing yogurt such as Lactobacillus bulgaricus, Lactococcus lactis, Streptococcus thermophilus, etc. can be used. When the pH reaches the target value, the curd formed is broken up by stirring and cooled to below 10 ° C. to obtain a fermented product. By cooling to 10 ° C. or less, the activity of lactic acid bacteria can be reduced to suppress the formation of an acid.
Next, the fermented product obtained in the fermentation step is subjected to heat treatment to obtain a fermented product after heating (fermented product after heat treatment). By appropriately heating the fermented product, it is possible to suppress the production of acid by lactic acid bacteria in the fermented product after heating. As a result, it is possible to suppress a decrease in pH during the subsequent production process and / or during storage of the concentrated fermented milk containing Bifidobacterium, and as a result, the survivability of Bifidobacterium can be improved.
Next, Lactobacillus paracasei NITE BP-01633 of the present invention is added to the fermented product after heating obtained in the heat treatment step. The amount of Lactobacillus paracasei NITE BP-01633 added is preferably 1 × 10 ⁷ to 1 × 10 ¹¹ CFU / ml, and 1 × 10 ⁸ to 1 × 10 ¹¹ CFU / ml of the fermented product after heating.
× 10 ¹⁰ CFU / ml is more preferred. When Lactobacillus paracasei NITE BP-01633 is dead, CFU / ml can be replaced with individual cells / ml.
After heating, Lactobacillus paracasei NITE BP-01633 is added to the fermented product and then concentrated. The concentration step can be carried out using a known concentration method as appropriate. For example, centrifugation or membrane separation can be used.
By taking the fermented milk obtained as described above, an intestinal regulation effect can be expected. Furthermore, prevention or constipation or diarrhea caused by irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease It can be used for treatment. Moreover, it can be used for the prevention or treatment of diarrhea resulting from food poisoning, infectious enteritis, ulcerative colitis or food allergy.

Claims (15)

  A composition for intestinal regulation, which comprises Lactobacillus paracasei NITE BP-01633 as an active ingredient.   The composition according to claim 1, wherein the Lactobacillus paracasei NITE BP-01633 is heat-killed.   The composition according to claim 2, wherein the heat-killed Lactobacillus paracasei NITE BP-01633 is crushed.   The composition for intestinal regulation according to any one of claims 1 to 3, which is used for the prevention or treatment of defecation disorder.   The composition for intestinal regulation according to claim 4, wherein the defecation disorder is constipation or diarrhea.   Said constipation or diarrhea is due to irritable bowel syndrome, pelvic floor dysfunction, congenital digestive tract dysfunction, intestinal obstruction, colon tumor, metabolic disease, central nervous system disease, peripheral nervous system disease or systemic disease, constipation The composition for intestinal regulation according to claim 5, wherein the composition is diarrhea.   The composition according to claim 5 or 6, wherein the constipation is delayed transit-type constipation, functional constipation, organic constipation or drug-induced constipation.   The composition according to claim 5, wherein the diarrhea is caused by food poisoning, infectious enteritis, ulcerative colitis or food allergy.   Furthermore, the intestinal tract according to any one of claims 1 to 8, further comprising Bifidobacterium bacteria and / or Lactobacillus bacteria (except for Lactobacillus paracasei NITE BP-01633). Composition.   The composition for intestinal regulation according to claim 9, wherein the Bifidobacterium is derived from a mammalian intestinal tract.   The composition for intestinal regulation according to claim 10, wherein the mammal is a human.   10. The Bifidobacterium genus bacteria is Bifidobacterium longum subspecies longum, Bifidobacterium infantis, Bifidobacterium breve, or Bifidobacterium bifidum. The composition for an intestinal regulation as described in any one of -11.   Said Lactobacillus genus bacteria (However, Lactobacillus paracasei NITE BP-01633 is excluded.), Lactobacillus plantarum, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus delbirickii subspecies bulgaricus, The composition for intestinal regulation according to any one of claims 9 to 12, which is Lactobacillus lactis.   The composition for intestinal regulation according to any one of claims 1 to 13, which is a food and drink composition.   The composition for intestinal regulation according to any one of claims 1 to 13, which is a pharmaceutical composition.

Images